Insights into Doublet Therapy and Clinical Trial Takeaways for Metastatic Prostate Cancer Treatment : Episode 5
Opinion
Video
Clinical Perspectives from the ARANOTE Trial in Metastatic Hormone-Sensitive Prostate Cancer
Author(s):
Key Takeaways
- Darolutamide's structure limits blood-brain barrier penetration, reducing central nervous system side effects and improving safety.
- It effectively delays metastasis and prolongs survival in non-metastatic castration-resistant prostate cancer.
Fred Saad, CQ, MD, FRCS, FCAHS, discusses how darolutamide offers potential advantages over other androgen receptor–targeted therapies for metastatic prostate cancer, including its unique molecular structure, favorable safety profile, and efficacy in specific clinical scenarios.
EP: 1.Therapeutic Combination Therapies for Metastatic Prostate Cancer
EP: 2.Patient-Centered Approach to Use of Chemotherapy in Metastatic Prostate Cancer
EP: 3.Inclusion of Chemotherapy and Impact on Outcomes From the ARASENS Trial
EP: 4.Patient Selection for Chemotherapy-Based Combination Regimens in Metastatic Prostate Cancer
Now Viewing
EP: 5.Clinical Perspectives from the ARANOTE Trial in Metastatic Hormone-Sensitive Prostate Cancer
EP: 6.Key Findings From ARANOTE: Darolutamide Plus ADT in mHSPC
Video Content above is prompted by the following:
- What are some of the benefits of darolutamide over other androgen receptor–targeted therapies?
Related Videos
Related Content
